Get access

How we manage prostate biopsy and prostate cancer therapy in men with haemophilia

Authors


Patrick F. Fogarty, MD, Director, Penn Comprehensive Hemophilia and Thrombosis Program, 3rd Floor Dulles Building, 3400 Spruce Street, Philadelphia, PA 19104, USA.
Tel.: 215 615 6555; fax: 215 615 6599;
e-mail: patrick.fogarty@uphs.upenn.edu

Abstract

A 56-year-old African American male with severe haemophilia A [baseline factor VIII (FVIII) activity <1%] and chronic hepatitis C virus infection started annual serial monitoring of prostate-specific antigen (PSA) at age 40 because of a family history of prostate cancer (his father died from the disease at age 63). His most recent PSA level was 4.4 ng L−1; previous values were <3 ng L−1. Digital rectal examination was unrevealing.

Ancillary